Trial intelligence / Profile preview

Autologous mesenchymal stem cells for subclinical renal allograft rejection after kidney transplantation

NL-OMON31649Active, not recruiting

Sponsor
Leiden University Medical Center
Start
Jan 2009
Modality
Stem Cell Therapies → Cell Therapies
Countries
1
01

Overview

Open-label, single-arm trial of autologous mesenchymal stem cells in kidney allograft rejection, sponsored by Leiden University Medical Center. Primary endpoints: Safety and Feasibility. Started Jan 2009; status: active, not recruiting.

02

Drugs

autologous mesenchymal stem cells
03

Conditions

kidney allograft rejection

Beyond the preview

Go deeper on NL-OMON31649.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON31649.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call